SOX2 expression in relation to clinicopathological characteristics in CRC.

<p>Abbreviations: MSI, microsatellite instability; MSS, microsatellite stable; CIMP, CpG island methylator phenotype (according to an eight-gene CIMP panel).</p>a<p>χ2 test.</p>b<p>The following numbers of missing cases were present: TNM stage, 12; localization, 5; grade, 7; MSI screening status, 15; CIMP status, 4; BRAF V600E, 8; KRAS, 7.</p>c<p>CIMP negative, no promoter hypermethylation; CIMP low, one to five genes methylated; CIMP high, six to eight genes methylated.</p

Cancer-specific survival analysis according to SOX2 expression.

<p>Shown are Kaplan-Meier plots of cancer-specific survival in (A) all CRC patients, (B) <i>BRAF^V600E</i> mutated CRC patients or (C) <i>BRAF</i> wild type CRC patients.</p

Expression of FGFR1 is increased in Caco2-SOX2 compared to Caco2.

<p>Expression of FGFR1, FGFR2, FGFR3 and FGFR4 by RT-PCR analysis in Caco2 cells and Caco2 cells stably overexpressing SOX2 (Caco2-SOX2). The expression in Caco2 was set as 1. *<i>p</i><0.05, n.s: non-significant <i>p</i>-value.</p

Representative immunohistochemical stainings of SOX2 expression in CRC tissue.

<p>(A) Negative nuclear SOX2 staining in a moderately differentiated CRC. (B) Positive nuclear SOX2 staining in a poorly differentiated CRC.</p

Real Time PCR analyses of SOX2 expression in CRC cell lines.

<p>(A) Caco2 cells, Caco2 cells stably expressing <i>BRAF</i> mutation (Caco2-BRAF^V600E) and Caco2 cells stably expressing <i>KRAS</i> mutation (Caco2-KRAS^G12V). SOX2 expression in Caco2 was set as 1. (B) Caco2 after cultivation with MEK-inhibitor, 24 or 48 h, or DMSO for 48 h as control. SOX2 expression in Caco2 treated with DMSO was set as 1. (C) Caco2-BRAF^V600E after cultivation with MEK-inhibitor, 24 or 48 h, or DMSO for 48 h as control. SOX2 expression in Caco2-BRAF^V600E treated with DMSO was set as 1. PD: PD98059 (MEK-inhibitor), *<i>p</i><0.05, **<i>p</i><0.01, ***<i>p</i><0.001, n.s: non-significant <i>p</i>-value.</p

SOX2 expression in primary CRC and corresponding liver metastasis.

<p>SOX2 expression in primary CRC and corresponding liver metastasis.</p